Tau Aggregation Inhibitors
What Are They, Tau Aggregation, and More
Author: Nikol Natalia Armata, MD
Editors: Alyssa Haag, Emily Miao, PharmD, Kelsey LaFayette, DNP
Illustrator: Jessica Reynolds, MS
Copyeditor: David G. Walker
What is tau?
Tau is a protein mainly found in the central nervous system and, more specifically, in the axonal compartment of neurons. Human tau protein is expressed by the single microtubule-associated protein tau (MAPT) gene located at chromosome 17. Despite its small size, tau protein plays a very important role in the proper functioning of the brain. This protein stabilizes the internal skeleton of neurons, forming a solid microtubule structure. One of the functions of the microtubule is to help transport nutrients and other essential substances from one part of the neuron to another.
In certain pathological situations, tau protein may undergo modifications that can result in the generation of atypical aggregates (i.e., large clusters usually formed by smaller misfolded particles) that are toxic to neurons. This process occurs in a number of neurological disorders collectively known as tauopathies. Tauopathies are characterized by excessive tau aggregates in neurons and glial cells. The most commonly recognized tauopathy is Alzheimer disease (AD). In individuals with Alzheimer disease, tau proteins are misfolded and abnormally shaped, causing the microtubule structure to collapse. Other known tauopathies include Huntington disease (HD), Pick disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and argyrophilic grain disease (AGD).
What is tau aggregation?
Tau aggregation refers to the abnormal association of the protein into larger clusters, which tend to be very insoluble, or difficult to resolve. The accumulation of tau aggregates in neurons directly correlates with microtubule dysfunction, thereby leading to neuronal degeneration and loss. Many reports have shown that the accumulation of tau aggregates is caused by post-translational modifications, including tau hyperphosphorylation (i.e., an increase in either the number of phosphorylated sites per tau molecule), acetylation (i.e., a chemical reaction within the protein during which a hydrogen atom is substituted for an acetyl group), and gene mutation (e.g., frameshift mutations associated with AD). The misfolded tau is self-assembled and forms tau oligomers (i.e., collection of a small number of repeating units, up to a few hundred), which can accumulate to form tau aggregates.
There is a specific region of tau that is responsible for microtubule binding and contains a large number of lysines, which is a positively charged amino acid. The positive charge of lysine allows tau to bind with the negatively-charged microtubules. When tau is abnormally hyperphosphorylated, the balance is disrupted and tau dissociates from microtubules. In this state, tau begins to aggregate.The onset and progression of tauopathies involve the formation of misfolded and oligomerized tau as well as the appearance of neurofibrillary tangles (NFT), which are aggregates of hyperphosphorylated tau protein. In addition to serving as markers for differential diagnosis and staging of disease, tau aggregates can worsen the progression of disease due to their neurotoxicity. Because tau protein aggregation is a purely pathological process unrelated to normal tau function, diverse strategies for inhibiting tau misfolding and aggregation are being investigated.
What are tau aggregation inhibitors?
Tau aggregation inhibitors are pharmacologic agents that aim to inhibit tau aggregation and prevent progression of certain conditions, like Alzheimer disease. There are several compounds that have shown promising results in in-vitro studies, such as methylene blue, emerging nutraceutic compounds (e.g., oleocanthal, curcumin, thiophene), diazodinitrophenol, and polythiophene compounds. However, thus far, methylene blue derivatives and curcumin are the only molecules that have advanced to clinical trials. The main focus of research has been on methylene blue, particularly its derivative called hydromethylthionine mesylate (HMTM), which is currently in phase III clinical trials.Another approach that aims to inhibit tau aggregation has emerged in pharmacology, which involves tau protein inhibitors (i.e., compounds that influence the behavior of tau proteins). Tau protein inhibitors include both substances that prevent tau aggregation and those that target other interactions or functions of tau proteins. More specifically, tau protein inhibitors could include agents that affect tau's interactions with microtubules, its phosphorylation state, or its cellular transport mechanisms. The main focus may include preventing aggregation as well as altering tau's behavior in ways that it is hypothesized could have therapeutic effects.
How do tau aggregation inhibitors work?
Tau aggregation inhibitors are designed to prevent or disrupt the process of tau protein misfolding and aggregation in neurodegenerative diseases. They work by targeting various stages of the aggregation process to prevent or minimize the formation of tau aggregates, thereby slowing disease progression. There are two main approaches to how these inhibitors work: by directly binding to tau (thereby altering its shape) or by breaking down existing aggregated tau complexes.
Inhibitors of tau aggregation, like HMTM, directly bind to the domain on the tau protein that contains high quantities of lysine, effectively blocking interactions between tau proteins themselves. In recent studies, in genetically modified tau mouse models, HMTM reduced tau pathology and behavioral impairments. Phase II and III trials conducted in humans have shown that HMTM is safe and has a low-risk side effect profile. Notably, HMTM at a dose of 16 milligrams per day (mg/day) revealed a statistically significant benefit in the cognitive and functional performance of individuals with moderate AD. Notably, tau aggregation inhibitors do not reverse pathology, especially if it is severe, but may help prevent further progression of disease.
Other tau inhibitors work by breaking existing tau aggregates, effectively disaggregating them into individual tau molecules. This process helps to reverse the harmful effects of tau aggregation and reduces the burden on brain cells. For example, curcumin, which is now undergoing clinical trials, attaches to low-strength tau and breaks down tau accumulations.
What are the most important facts to know about tau aggregation inhibitors?
The microtubule-associated protein tau is a crucial protein of the central nervous system, found mainly in the axonal compartments of neurons. It stabilizes neuron structures and facilitates vital substance transportation. In pathological situations, tau may misfold into toxic aggregates, causing tauopathies like Alzheimer disease. Tau aggregation refers to abnormal clustering, correlating with microtubule dysfunction and neuron loss, and can be triggered by post-translational modifications and gene mutations. Tau aggregation inhibitors are medications that aim to prevent the harmful clumping of tau proteins to prevent progression of certain neurodegenerative conditions. Promising tau aggregation inhibitors include methylene blue derivatives, like hydromethylthionine mesylate (HMTM), and curcumin. Tau aggregation inhibitors work by binding directly to tau or by breaking down existing tau aggregates. Hydromethylthionine mesylate has demonstrated encouraging results in trials, offering hope for Alzheimer treatment.
Quiz yourself on Tau Aggregation Inhibitors
5 Questions availableQuiz now!
18 Flashcards availableQuiz now!
Watch related videos:
Related linksAlzheimer disease
Huntington disease: Year of the Zebra
Medications for neurodegenerative diseases
Resources for research and reference
Aillaud I, Funke SA. Tau aggregation inhibiting peptides as potential therapeutics for Alzheimer disease. Cellular and Molecular Neurobiology. 2022;43(951–961). doi:10.1007/s10571-022-01230-7
Cisek K, Cooper GL, Huseby CJ, Kuret J. Structure and mechanism of action of tau aggregation inhibitors. Curr Alzheimer Res. 2014;11(10):918-927. doi:10.2174/1567205011666141107150331
Dominguez-Meijide A, Vasili E, Outeiro TF. Pharmacological modulators of tau aggregation and spreading. Brain Sciences. 2020;10(11):858. doi:10.3390/brainsci10110858
Lippens G, Sillen A, Landrieu I, et al. Tau aggregation in Alzheimer's disease: what role for phosphorylation?. Prion. 2007;1(1):21-25. doi:10.4161/pri.1.1.4055Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO. Oral tau aggregation inhibitor for Alzheimer's disease: Design, progress and basis for selection of the 16 mg/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate. J Prev Alzheimers Dis. 2022;9(4):780-790. doi:10.14283/jpad.2022.63